logo

For the Inventor, By the Inventor

Rilly la Montagne, France

Jean-Marc M Girodeau

This inventor holds 15 USPTO granted patents. Top assignees: Ici Pharma, Imperial Chemical Industries Limited, Zeneca Limited. Active years: 1992-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Marc M Girodeau. Retrieved from https://idiyas.com/inventor/jean-marc-m-girodeau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 100.0

Average Co-Inventor Count = 1.9

ph-index = 8

Forward Citations = 139(Granted Patents)


Location History:

  • Rilly la Montagne, FR (1992 - 1995)
  • Puisieulx, FR (1993 - 1995)

Company Filing History:

goldMedal14 out of 80 
 
Ici Pharma
 patents
silverMedal12 out of 3,840 
 
Imperial Chemical Industries Limited
 patents
bronzeMedal2 out of 854 
 
Zeneca Limited
 patents
4. 1 out of 1 
 
Imperial Chemistries Industries Plc
 patent
5. 1 out of 2 
 
Zeneca Pharma
 patents
where one patent can have more than one assignee

Years Active: 1992-1995

Loading Chart...
15 patents (USPTO):Explore Patents
1. 5446043 - Isoquinolyl, quinoxalinyl and quinazolinyl derivatives as inhibitors of (1995-08-29),
2. 5403859 - Heterocyclic derivatives (1995-04-04),
3. 5401751 - Isoquinoline derivatives suitable for use in leukotriene mediated disease (1995-03-28),
4. 5350754 - Heterocyclic cycloalkanes (1994-09-27),
5. 5236919 - Quinoxalinyl derivatives suitable for use in leukotriene mediated disease (1993-08-17),
6. 5234950 - Tetrahydrofuran derivatives (1993-08-10),
7. 5217977 - Heterocyclic cycloalkanes (1993-06-08),
8. 5214069 - Alcohol and ether derivatives (1993-05-25),
9. 5202326 - Heterocyclic ethers (1993-04-13),
10. 5196422 - 5-lipoxygenase inhibiting thiazoles (1993-03-23),
11. 5134148 - Heterocycles for use as inhibitors of leukotrienes (1992-07-28),
12. 5132328 - Alcohol and ether derivatives (1992-07-21),
13. 5105020 - Cycloalkane derivatives (1992-04-14),
14. 5098930 - Heterocyclic derivatives (1992-03-24),
15. 5089513 - 5-lipoxygenase inhibitory thiazoles (1992-02-18),

Title: The Innovative Journey of Jean-Marc M Girodeau

Introduction

Jean-Marc M Girodeau, a prolific inventor based in Rilly la Montagne, France, boasts an impressive portfolio comprising 15 patents. His work in the field of heterocyclic chemistry has garnered attention for its potential applications in various industries.

Latest Patents

Among his notable inventions are the isoquinolyl, quinoxalinyl, and quinazolinyl derivatives as inhibitors. These latest patents delve into the structural complexities of heterocyclic cycloalkanes, showcasing a defined formula that highlights the use of optional substitutions in 6-membered monocyclic or 10-membered bicyclic heterocyclic moieties containing nitrogen atoms. Additionally, his work on heterocyclic derivatives focuses on a specific formula featuring optionally substituted phenyl or naphthyl groups.

Career Highlights

Jean-Marc's remarkable career includes significant contributions while working with prestigious companies such as ICI Pharma and Imperial Chemical Industries Limited. His expertise in chemical innovation has made a lasting impact on the pharmaceutical industry.

Collaborations

Throughout his career, Jean-Marc has collaborated with esteemed colleagues, including Graham C Crawley and Philip N Edwards. Their combined efforts have further advanced the field of heterocyclic chemistry, ultimately benefiting various research and development projects.

Conclusion

In conclusion, Jean-Marc M Girodeau stands as a notable figure in the world of innovation, with a strong patent portfolio and a rich history of collaboration. His contributions to chemical sciences continue to inspire advancements in numerous applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…